BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6187080)

  • 1. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.
    Torisu M; Katano M; Kimura Y; Itoh H; Takesue M
    Surgery; 1983 Mar; 93(3):357-64. PubMed ID: 6187080
    [No Abstract]   [Full Text] [Related]  

  • 2. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.
    Katano M; Torisu M
    Surgery; 1983 Mar; 93(3):365-73. PubMed ID: 6600854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
    Katano M
    Fukuoka Igaku Zasshi; 1981 Oct; 72(10):543-55. PubMed ID: 7327499
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological parameters in gastric cancer patients treated with immunotherapy of streptococcal preparation OK-432.
    Hanaue H; Nomoto S; Kimura T; Kutsuna T; Takeuchi T; Yoshizaki S
    Keio J Med; 1982 Dec; 31(4):159-68. PubMed ID: 6985379
    [No Abstract]   [Full Text] [Related]  

  • 5. Malignant ascites treated with streptococcal extract.
    Lancet; 1983 Jun; 1(8336):1258. PubMed ID: 6134047
    [No Abstract]   [Full Text] [Related]  

  • 6. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
    Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells].
    Katano M; Yamamoto H; Hisatsugu T
    Nihon Geka Gakkai Zasshi; 1986 Apr; 87(4):471. PubMed ID: 3713694
    [No Abstract]   [Full Text] [Related]  

  • 8. [Non-specific immunotherapy with OK-432, streptococcus pyogenes preparation, for inoperable cancer patients of the digestive tract].
    Hanaue H; Nomoto S; Yoshizaki S; Kitano Y; Miyakawa S; Horie F; Kurosawa T; Nemoto A; Yasuda H; Takada T
    Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1307-14. PubMed ID: 6512346
    [No Abstract]   [Full Text] [Related]  

  • 9. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
    Hayashi Y; Torisu M
    Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy].
    Sekizuka H; Noro K; Haruyama S; Kiribuchi Y; Hayashi F
    Gan No Rinsho; 1985 Sep; 31(11):1381-6. PubMed ID: 3877822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. II. Experimental study using human malignant ascites].
    Umemoto T; Saji S; Oonishi A; Kunii Y; Goshima H; Tachibana S; Takao H; Tanemura H; Sakata K
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1512-7. PubMed ID: 3183459
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of streptococcal preparation OK-432 for gastric cancer patients--comparison between intradermal and intramuscular injection.
    Hanaue H; Kurosawa T; Yoshizaki S; Shikata J
    Jpn J Surg; 1984 May; 14(3):191-7. PubMed ID: 6611437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical trial of oral immunotherapy with streptococcal preparation OK 432 on gastric cancer].
    Nio Y; Ohgaki K; Henmi K; Kan N; Inamoto T; Tsuchitani T; Kodama H; Tobe T
    Nihon Gan Chiryo Gakkai Shi; 1982 Apr; 17(3):728-34. PubMed ID: 6752308
    [No Abstract]   [Full Text] [Related]  

  • 14. [Administration of hemolytic streptococcus preparation OK-432 on recurrent gastric carcinoma].
    Hanaue H; Kurosawa T; Kitano Y; Miyagawa S; Nemoto A; Yamato H; Asagoe T; Shikata J
    Nihon Gan Chiryo Gakkai Shi; 1987 Aug; 22(7):1367-72. PubMed ID: 3501455
    [No Abstract]   [Full Text] [Related]  

  • 15. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
    Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of malignant ascites. I. Clinical studies on intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
    Katano M
    Fukuoka Igaku Zasshi; 1981 Oct; 72(10):532-42. PubMed ID: 7327498
    [No Abstract]   [Full Text] [Related]  

  • 17. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy].
    Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T
    Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
    Mori H; Itoh N; Tamaya T
    Immunopharmacol Immunotoxicol; 1989; 11(1):33-53. PubMed ID: 2503555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient with gastric carcinoma improved remarkably on intraperitoneal OK-432 therapy.
    Yamagishi H; Ishibashi H; Kodama M; Tanaka T; Harada Y; Hashimoto I
    Jpn J Surg; 1982; 12(6):434-41. PubMed ID: 7166915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
    Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.